Arcus launches stock offering to fund kidney cancer drug push

What's the deal? Arcus Biosciences (NYSE: RCUS) has commenced an underwritten public offering of its common stock, with all shares sold by the company. Jefferies, Leerink PartnersDealroom has a profile for this one. Try Dealroom →, and TD Cowen are acting as joint book-running managers, and underwriters will have a 30-day option to buy up to an additional 15% of the shares offered.

Why now? The raise follows a run of fresh data for casdatifan, Arcus's investigational HIF-2α inhibitor for clear cell renal cell carcinoma (ccRCC). The company presented new ARC-20 results at an October investor event in New York, days before launching the offering.

What's the endgame? Arcus wants casdatifan to become a backbone therapy across first-, second-, and late-line kidney cancer treatment. It is running a Phase 3 study of casdatifan plus cabozantinib and plans to start its first-line PEAK-20 trial by year-end.

The new data looked encouraging: a 14.5-month median progression-free survival for the second-line combination and a 50% response rate in a small first-line cohort. Arcus reported $775 million in cash and equivalents at the end of the second quarter, with runway into at least the second half of 2028.

What could go wrong? The ARC-20 figures are early, non-randomized data, and comparisons with other treatments are benchmarks rather than head-to-head evidence. The offering itself is subject to market conditions, with no assurance it completes or at what size.

The signal: Arcus is tapping public markets to fund an increasingly broad and costly clinical program. The data give a rationale for betting big on casdatifan — not proof that it will become a standard treatment.

Read more: business.theantlersamerican.com

Image credit: National Institutes of Health (NIH)